New treatments for COPD

Current Opinion in Pharmacology

Volumn 13, Issue 3, 2013, Pages 362-369

  Ngkelo, Anta ^a   Adcock, Ian M ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABEDITEROL; AMFEBUTAMONE; BRONCHODILATING AGENT; CARMOTEROL; CHEMOKINE; CORTICOSTEROID; CYT002 NICQB; CYTOKINE; DILMAPIMOD; FORMOTEROL; GSK 598809; I KAPPA B; INDACATEROL; INFLIXIMAB; JANUS KINASE INHIBITOR; LEUKOCYTE ELASTASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NICOTINE QBETA; NICOTINE VACCINE; NORFLURANE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHODIESTERASE IV; PLACEBO; ROFLUMILAST; SALMETEROL; STAT PROTEIN; TIOTROPIUM BROMIDE; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARENICLINE; VILANTEROL;

ABSENCE OF SIDE EFFECTS; ANTIINFLAMMATORY ACTIVITY; ASTHMA; CARDIOTOXICITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); COMBINATION CHEMOTHERAPY; DRUG MECHANISM; DRUG TARGETING; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; INFLAMMATION; NICOTINE REPLACEMENT THERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SMOKING; SMOKING CESSATION; STEM CELL; TISSUE REGENERATION; TOBACCO DEPENDENCE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BRONCHODILATOR AGENTS; HUMANS; LUNG; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REGENERATION; SMOKING CESSATION;

EID: 84879113970     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2013.03.014     Document Type: Review

References (67)

1. M. Decramer, W. Janssens, and M. Miravitlles Chronic obstructive pulmonary disease Lancet 379 2012 1341 1351
2. J. Vestbo, S.S. Hurd, A.G. Agusti, P.W. Jones, C. Vogelmeier, A. Anzueto, P.J. Barnes, L.M. Fabbri, F.J. Martinez, M. Nishimura, R.A. Stockley, D.D. Sin, and R. Rodriguez-Roisin Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease GOLD executive summary Am J Respir Crit Care Med 187 2013 347 365
3. D.M. Mannino, and A.S. Buist Global burden of COPD: risk factors, prevalence, and future trends Lancet 370 2007 765 773
4. G.G. Brusselle, G.F. Joos, and K.R. Bracke New insights into the immunology of chronic obstructive pulmonary disease Lancet 378 2011 1015 1026
5. I.M. Adcock, G. Caramori, and P.A. Kirkham Strategies for improving the efficacy and therapeutic ratio of glucocorticoids Curr Opin Pharmacol 12 2012 246 251
6. I. Rahman, and W. Macnee Antioxidant pharmacological therapies for COPD Curr Opin Pharmacol 12 2012 256 265
7. L. Puente-Maestu, A. Tejedor, A. Lazaro, M.J. de, L. Alvarez-Sala, F. Gonzalez-Aragoneses, C. Simon, and A. Agusti Site of mitochondrial reactive oxygen species production in skeletal muscle of chronic obstructive pulmonary disease and its relationship with exercise oxidative stress Am J Respir Cell Mol Biol 47 2012 358 362
8. R.M. Tuder, and I. Petrache Pathogenesis of chronic obstructive pulmonary disease J Clin Invest 122 2012 2749 2755
9. L. Nici, and R. ZuWallack An official American Thoracic Society workshop report: the Integrated Care of the COPD Patient Proc Am Thorac Soc 9 2012 9 18
10. K. Pirie, R. Peto, G.K. Reeves, J. Green, and V. Beral The 21st century hazards of smoking and benefits of stopping: a prospective study of one million women in the UK Lancet 381 2012 133 141
11. E.J. Mills, P. Wu, I. Lockhart, K. Thorlund, M. Puhan, and J.O. Ebbert Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: a systematic review and multiple treatment meta-analysis Ann Med 44 2012 588 597
12. N. Islam, and S. Rahman Improved treatment of nicotine addiction and emerging pulmonary drug delivery Drug Discov Ther 6 2012 123 132
13. D. Harmey, P.R. Griffin, and P.J. Kenny Development of novel pharmacotherapeutics for tobacco dependence: progress and future directions Nicotine Tob Res 14 2012 1300 1318
14. M.G. Matera, C.P. Page, and M. Cazzola Novel bronchodilators for the treatment of chronic obstructive pulmonary disease Trends Pharmacol Sci 32 2011 495 506
15. M. Cazzola, C.P. Page, L. Calzetta, and M.G. Matera Pharmacology and therapeutics of bronchodilators Pharmacol Rev 64 2012 450 504
16. E.D. Bateman, S. Rennard, P.J. Barnes, P.V. Dicpinigaitis, R. Gosens, N.J. Gross, J.A. Nadel, M. Pfeifer, K. Racké, K.F. Rabe, B.K. Rubin, T. Welte, and I. Wessler Alternative mechanisms for tiotropium Pulm Pharmacol Ther 22 2009 533 542
17. D.P. Tashkin, B. Celli, S. Senn, D. Burkhart, S. Kesten, S. Menjoge, M. Decramer, and UPLIFT Study Investigators A 4-year trial of tiotropium in chronic obstructive pulmonary disease N Engl J Med 359 2008 1543 1554
18. S.P. Peters, S.J. Kunselman, N. Icitovic, W.C. Moore, R. Pascual, B.T. Ameredes, H.A. Boushey, W.J. Calhoun, M. Castro, R.M. Cherniack, T. Craig, L. Denlinger, L.L. Engle, E.A. DiMango, J.V. Fahy, E. Israel, N. Jarjour, S.D. Kazani, M. Kraft, S.C. Lazarus, R.F. Lemanske Jr., N. Lugogo, R.J. Martin, D.A. Meyers, J. Ramsdell, C.A. Sorkness, E.R. Sutherland, S.J. Szefler, S.I. Wasserman, M.J. Walter, M.E. Wechsler, V.M. Chinchilli, E.R. Bleecker, and National Heart Lung, and Blood Institute Asthma Clinical Research Network Tiotropium bromide step-up therapy for adults with uncontrolled asthma N Engl J Med 363 2010 1715 1726
19. J. Chong, C. Karner, and P. Poole Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease Cochrane Database Syst Rev 9 2012 CD009157
20. G.F. Joos, V.J. Schelfhout, R.A. Pauwels, F. Kanniess, H. Magnussen, R. Lamarca, J.M. Jansat, and G.E. Garcia Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients Respir Med 104 2010 865 872
21. L.J. Nannini, T.J. Lasserson, and P. Poole Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease Cochrane Database Syst Rev 9 2012 CD006829
22. N.A. Hanania, G.D. Crater, A.N. Morris, A.H. Emmett, D.M. O'Dell, and D.E. Niewoehner Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD Respir Med 106 2012 91 101
23. K.S. Jung, H.Y. Park, S.Y. Park, S.K. Kim, Y.K. Kim, J.J. Shim, H.S. Moon, K.H. Lee, J.H. Yoo, and S.D. Lee Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study Respir Med 106 2012 382 389
24. R.O. Salama, P.M. Young, P. Rogueda, A. Lallement, I. Iliev, and D. Traini Advances in drug delivery: is triple therapy the future for the treatment of chronic obstructive pulmonary disease? Expert Opin Pharmacother 12 2011 1913 1932
25. M.A. Giembycz, and R. Newton Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases: dual-selective phosphodiesterase inhibitors and novel combination therapies Handb Exp Pharmacol 2011 415 446
26. L.M. Fabbri, P.M. Calverley, J.L. Izquierdo-Alonso, D.S. Bundschuh, M. Brose, F.J. Martinez, and K.F. Rabe Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials Lancet 374 2009 695 703
27. P.M. Calverley, K.F. Rabe, U.M. Goehring, S. Kristiansen, L.M. Fabbri, and F.J. Martinez Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials Lancet 374 2009 685 694
28. M.A. Giembycz, and S.K. Field Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD Drug Des Devel Ther 4 2010 147 158
29. P.J. Barnes Development of new drugs for COPD Curr Med Chem 20 2013 19
30. C. Pridgeon, L. Bugeon, L. Donnelly, U. Straschil, S.J. Tudhope, P. Fenwick, J.R. Lamb, P.J. Barnes, and M.J. Dallman Regulation of IL-17 in chronic inflammation in the human lung Clin Sci (Lond) 120 2011 515 524
31. S.A. Jones, J. Scheller, and S. Rose-John Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling J Clin Invest 121 2011 3375 3383
32. P.A. Kirkham, G. Caramori, P. Casolari, A.A. Papi, M. Edwards, B. Shamji, K. Triantaphyllopoulos, F. Hussain, M. Pinart, Y. Khan, L. Heinemann, L. Stevens, M. Yeadon, P.J. Barnes, K.F. Chung, and I.M. Adcock Oxidative stress-induced antibodies to carbonyl-modified protein correlate with severity of chronic obstructive pulmonary disease Am J Respir Crit Care Med 184 2011 796 802
33. I.D. Pavord, S. Korn, P. Howarth, E.R. Bleecker, R. Buhl, O.N. Keene, H. Ortega, and P. Chanez Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial Lancet 380 2012 651 659
34. J. Corren, R.F. Lemanske, N.A. Hanania, P.E. Korenblat, M.V. Parsey, J.R. Arron, J.M. Harris, H. Scheerens, L.C. Wu, Z. Su, S. Mosesova, M.D. Eisner, S.P. Bohen, and J.G. Matthews Lebrikizumab treatment in adults with asthma N Engl J Med 365 2011 1088 1098
35. A. Stadtmann, and A. Zarbock CXCR2: from bench to bedside Front Immunol 3 2012 263
36. R. Virtala, A.K. Ekman, L. Jansson, U. Westin, and L.O. Cardell Airway inflammation evaluated in a human nasal lipopolysaccharide challenge model by investigating the effect of a CXCR2 inhibitor Clin Exp Allergy 42 2012 590 596
37. R.J. Snelgrove Targeting of a common receptor shared by CXCL8 and N-Ac-PGP as a therapeutic strategy to alleviate chronic neutrophilic lung diseases Eur J Pharmacol 667 2011 1 5
38. E. Pace, M. Ferraro, L. Siena, M. Melis, A.M. Montalbano, M. Johnson, M.R. Bonsignore, G. Bonsignore, and M. Gjomarkaj Cigarette smoke increases Toll-like receptor 4 and modifies lipopolysaccharide-mediated responses in airway epithelial cells Immunology 124 2008 401 411
39. S. Basith, B. Manavalan, G. Lee, S.G. Kim, and S. Choi Toll-like receptor modulators: a patent review (2006-2010) Expert Opin Ther Pat 21 2011 927 944
40. G.F. Bezemer, S. Sagar, J. van Bergenhenegouwen, N.A. Georgiou, J. Garssen, A.D. Kraneveld, and G. Folkerts Dual role of Toll-like receptors in asthma and chronic obstructive pulmonary disease Pharmacol Rev 64 2012 337 358
41. J.H. Kwak, J.K. Jung, and H. Lee Nuclear factor-kappa B inhibitors; a patent review (2006-2010) Expert Opin Ther Pat 21 2011 1897 1910
42. M. Pasparakis Role of NF-kappaB in epithelial biology Immunol Rev 246 2012 346 358
43. K.F. Chung p38 mitogen-activated protein kinase pathways in asthma and COPD Chest 139 2011 1470 1479
44. A. Banerjee, C. Koziol-White, and R. Panettieri Jr. p38 MAPK inhibitors IKK2 inhibitors, and TNFalpha inhibitors in COPD Curr Opin Pharmacol 12 2012 287 292
45. D.S. Millan, M.E. Bunnage, J.L. Burrows, K.J. Butcher, P.G. Dodd, T.J. Evans, D.A. Fairman, S.J. Hughes, I.C. Kilty, A. Lemaitre, R.A. Lewthwaite, A. Mahnke, J.P. Mathias, J. Philip, R.T. Smith, M.H. Stefaniak, M. Yeadon, and C. Phillips Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease J Med Chem 54 2011 7797 7814
46. S.D. Lucas, E. Costa, R.C. Guedes, and R. Moreira Targeting COPD: advances on low-molecular-weight inhibitors of human neutrophil elastase Med Res Rev 2011 10.1002/med.20247
47. R.E. Vandenbroucke, E. Dejonckheere, and C. Libert A therapeutic role for matrix metalloproteinase inhibitors in lung diseases? Eur Respir J 38 2011 1200 1214
48. W.P. Fung-Leung Phosphoinositide 3-kinase delta (PI3Kdelta) in leukocyte signaling and function Cell Signal 23 2011 603 608
49. J.A. Marwick, G. Caramori, P. Casolari, F. Mazzoni, P.A. Kirkham, I.M. Adcock, K.F. Chung, and A. Papi A role for phosphoinositol 3-kinase delta in the impairment of glucocorticoid responsiveness in patients with chronic obstructive pulmonary disease J Allergy Clin Immunol 125 2010 1146 1153
50. J. Doukas, L. Eide, K. Stebbins, A. Racanelli-Layton, L. Dellamary, M. Martin, E. Dneprovskaia, G. Noronha, R. Soll, W. Wrasidlo, L.M. Acevedo, and D.A. Cheresh Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease J Pharmacol Exp Ther 328 2009 758 765
51. P.S. Bakke, G. Zhu, A. Gulsvik, X. Kong, A.G. Agusti, P.M. Calverley, C.F. Donner, R.D. Levy, B.J. Make, P.D. Pare, S.I. Rennard, J. Vestbo, E.F. Wouters, W. Anderson, D.A. Lomas, E.K. Silverman, and S.G. Pillai Candidate genes for COPD in two large data sets Eur Respir J 37 2011 255 263
52. P. Qu, J. Roberts, Y. Li, M. Albrecht, O.W. Cummings, J.N. Eble, H. Du, and C. Yan Stat3 downstream genes serve as biomarkers in human lung carcinomas and chronic obstructive pulmonary disease Lung Cancer 63 2009 341 347
53. R. Fleischmann, J. Kremer, J. Cush, H. Schulze-Koops, C.A. Connell, J.D. Bradley, D. Gruben, G.V. Wallenstein, S.H. Zwillich, and K.S. Kanik Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis N Engl J Med 367 2012 495 507
54. W.J. Sandborn, S. Ghosh, J. Panes, I. Vranic, C. Su, S. Rousell, and W. Niezychowski Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis N Engl J Med 367 2012 616 624
55. J.A. Marwick, I.M. Adcock, and K.F. Chung Overcoming reduced glucocorticoid sensitivity in airway disease: molecular mechanisms and therapeutic approaches Drugs 70 2010 929 948
56. P.E. Pergola, P. Raskin, R.D. Toto, C.J. Meyer, J.W. Huff, E.B. Grossman, M. Krauth, S. Ruiz, P. Audhya, H. Christ-Schmidt, J. Wittes, and D.G. Warnock Bardoxolone methyl and kidney function in CKD with type 2 diabetes N Engl J Med 365 2011 327 336
57. D. Malhotra, R.K. Thimmulappa, N. Mercado, K. Ito, P. Kombairaju, S. Kumar, J. Ma, D. Feller-Kopman, R. Wise, P. Barnes, and S. Biswal Denitrosylation of HDAC2 by targeting Nrf2 restores glucocorticosteroid sensitivity in macrophages from COPD patients J Clin Invest 121 2011 4289 4302
58. P.A. Ford, A.L. Durham, R.E. Russell, F. Gordon, I.M. Adcock, and P.J. Barnes Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD Chest 137 2010 1338 1344
59. O.S. Usmani, and P.J. Barnes Assessing and treating small airways disease in asthma and chronic obstructive pulmonary disease Ann Med 44 2012 146 156
60. N. Barnes, D. Price, G. Colice, A. Chisholm, P. Dorinsky, E.V. Hillyer, A. Burden, A.J. Lee, R.J. Martin, N. Roche, Z.J. von, and E. Israel Asthma control with extrafine-particle hydrofluoroalkane-beclometasone vs. large-particle chlorofluorocarbon-beclometasone: a real-world observational study Clin Exp Allergy 41 2011 1521 1532
61. V. Muller, G. Galffy, N. Eszes, G. Losonczy, A. Bizzi, G. Nicolini, H. Chrystyn, and L. Tamasi Asthma control in patients receiving inhaled corticosteroid and long-acting beta2-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulation BMC Pulm Med 11 2011 40
62. M. Hind, A. Gilthorpe, S. Stinchcombe, and M. Maden Retinoid induction of alveolar regeneration: from mice to man? Thorax 64 2009 451 457
63. S. Rankin Mesenchymal stem cells Thorax 67 2012 565 566
64. D.J. Weiss, R. Casaburi, R. Flannery, M. Leroux-Williams, and D.P. Tashkin A placebo-controlled randomized trial of mesenchymal stem cells in chronic obstructive pulmonary disease Chest 2012 10.1378/chest.12-2094
65. S.S. Salvi, and P.J. Barnes Chronic obstructive pulmonary disease in non-smokers Lancet 374 2009 733 743
66. A. Berndt, A.S. Leme, and S.D. Shapiro Emerging genetics of COPD EMBO Mol Med 4 2012 1144 1155
67. A.S. Gershon, L. Warner, P. Cascagnette, J.C. Victor, and T. To Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population study Lancet 378 2011 991 996